At screening , 62.3 % of patients in the prucalopride group and 55.1 % in the placebo group had a history of fecal incontinence ; 60.4 % and 55.1 % in the prucalopride and placebo groups , respectively , had a mean of 1 spontaneous bowel movements/week .